The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; Amgen; Bayer; Eisai; Gilead Sciences; Incyte; Ipsen; Lilly; Merck Serono; Roche; Sanofi
Consulting or Advisory Role - Amgen; ArQule; AstraZeneca; Basilea; Bayer; Bristol-Myers Squibb; Celgene; Eisai; Exelixis; Genenta Science; Hengrui Medicine; Incyte; Ipsen; IQVIA; Lilly; MSD; Nerviano Medical Sciences; Roche; Sanofi; SERVIER; Zymeworks
Research Funding - Agios; ARMO BioSciences; AstraZeneca; BeiGene; Eisai; Exelixis; FibroGen; Incyte; Ipsen; Lilly; MSD; Nerviano Medical Sciences; Roche; Zymeworks
Travel, Accommodations, Expenses - Ipsen
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Legend Biotech; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); Sillajen; SOBI (I); Surface Oncology; TheraBionic; twoXAR; Vector Health; Yiviva; Yiviva
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)
Travel, Accommodations, Expenses - Polaris
 
Stephen Lam Chan
Honoraria - AstraZeneca; Eisai; MSD
Consulting or Advisory Role - AstraZeneca; Eisai; MSD Oncology
Research Funding - Eisai; Ipsen
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - BMS; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Ono Pharmaceutical; Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
George Lau
No Relationships to Disclose
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exact Sciences; Genentech/Roche; Gilead Sciences; Merck (Inst)
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Wattana Sukeepaisarnjaroen
No Relationships to Disclose
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Blueprint Medicines; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Novartis; Surface Oncology; Zymeworks
 
Tu V. Dao
No Relationships to Disclose
 
Enrico N. De Toni
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Pfizer; Roche; TERUMO
Research Funding - AstraZeneca; Bayer; Bristol-Myer Squibb; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Celsion; Roche
 
Lorenza Rimassa
No Relationships to Disclose
 
Valeriy Vladimirovich Breder
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda
 
Alexander Vasilyev
No Relationships to Disclose
 
Alexandra Heurgue
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Intercept Pharmaceuticals; Ipsen
 
Vincent Tam
Honoraria - Apobiologix; AstraZeneca; Eisai; Incyte; Ipsen; Roche
Research Funding - Eisai; Ipsen; Roche
 
Kabir Mody
Stock and Other Ownership Interests - CytoDyn; Oncotherapeutics
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Ipsen; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; AstraZeneca (Inst); Basilea (Inst); FibroGen; Gritstone Bio (Inst); Incyte (Inst); MedImmune; Merck (Inst); Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma; Turnstone Bio (Inst); Vyriad (Inst)
 
Satheesh Chiradoni Thungappa
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca; Eisai
 
Philip He
Employment - AstraZeneca; Sanofi (I)
Stock and Other Ownership Interests - AstraZeneca; Celldex; Sanofi (I)
 
Alejandra Negro
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Bruno Sangro
Consulting or Advisory Role - Adaptimmune; AstraZeneca; Bayer; Bristol-Myers Squibb; BTG; Eisai; H3 Biomedicine; Incyte; Ipsen; Lilly; Merck; Roche/Genentech; Sirtex Medical
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Incyte; Ipsen; Lilly; Roche; Sirtex Medical
Research Funding - Bristol-Myers Squibb (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Sirtex Medical
Other Relationship - Medscape; Target Pharmasolutions